Adlai Nortye Biopharma
As of the edition of 20 October 2026, Adlai Nortye Biopharma runs 5 drugs; it is on route A at 4 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Active | 3 |
| Stopped | 2 |
| Total | 5 |
Where it needs a new molecule
Route A at 4 targets, route B at 0 targets.
| Target | Route |
|---|---|
| PIK3CB Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Route A |
| PIK3CG Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Route A |
| PIK3CD Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Route A |
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Adlai Nortye Biopharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 4 trials led
- Digestive system: 2 trials led
- Nervous system: 2 trials led